Steroid Hormone Agonists and Antagonists in the Treatment of Cancer

References

• King W J, Greene G L. Monoclonal antibodies localize estrogen receptor in the nuclei of target cells. Nature 1984; 307: 745–749
   PubMed Web of Science ®Google Scholar
• Welshons W V, Leiberman M E, Gorski J. Nuclear localization of unoccupied estrogen receptors. Nature 1984; 307: 747–749
   PubMed Web of Science ®Google Scholar
• Greene G L, Sobel G N, King W J. Immunochemical studies of estrogen receptors. J Steroid Biochem 1984; 20: 51–56
   PubMedGoogle Scholar
• Walter P, Green S, Greene G. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci (USA) 1985; 82: 7889–7893
   PubMed Web of Science ®Google Scholar
• Kurst A, Green S, Argos P. The chicken oestrogen receptor sequence: homology with v-erbA and the human oestrogen and glucocorticoid receptors. EMBO J 1986; 5: 891–897
   PubMed Web of Science ®Google Scholar
• Kumar V, Green S, Staub A. Localisation of the oestradiol-binding and putative DNA-binding domains of the human oestrogen receptor. EMBO J 1986; 5: 2231–2236
   PubMed Web of Science ®Google Scholar
• Green S, Walter P, Kumar V. Human oestrogen receptor cDNA: sequence, expression and homology to v-eri-a. Nature 1986; 320: 134–139
   PubMed Web of Science ®Google Scholar
• Kumar V, Green S, Stack G. Functional domains of the human estrogen receptor. Cell 1987; 51: 941–951
   PubMed Web of Science ®Google Scholar
• Hollenberg S M, Weinberger C, Ong E S. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635–641
   PubMed Web of Science ®Google Scholar
• Jeltsch J M, Krozowski Z, Quirin-Stricker C. Cloning of the chicken progesterone receptor. Proc Natl Acad Sci (USA) 1984; 83: 5424–5428
   Web of Science ®Google Scholar
• Weinberger C, Hollenberg S M, Rosenfeld M G. Domain structure of human glucocorticoid receptor and its relationship to the v-erb A oncogene product. Nature 1985; 318: 670–672
   PubMed Web of Science ®Google Scholar
• Weinberger C, Thompson C C, Ong E S. The c-erfr-A encodes a thyroid hormone receptor. Nature 1986; 324: 641–646
   PubMed Web of Science ®Google Scholar
• McDonnell D P, Mangelsdorf D J, Pike J W. Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science 1987; 235: 1214–1217
   PubMed Web of Science ®Google Scholar
• Patkovich M, Brand N J, Krust A. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987; 330: 444–450
   PubMed Web of Science ®Google Scholar
• Arriza J L, Weinberger C, Cerelli G. Cloning of the human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987; 317: 268–275
   Google Scholar
• Trapman J, Klaassen P, Kuiper G. Cloning, structure, and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Comm 1988; 153: 241–248
   PubMed Web of Science ®Google Scholar
• Chang C, Kokontis J, Liao S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 1988; 240: 324–326
   PubMed Web of Science ®Google Scholar
• Lubahn D B, Joseph D R, Sullivan P M. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 1988; 240: 327–330
   PubMed Web of Science ®Google Scholar
• Weinberger C, Thompson C C, Ong E S. The c-erb-A gene encodes a thyroid hormone receptor. Nature 1986; 284: 641–646
   Google Scholar
• Webster N JG, Green S, Jin J R, Chambon P. The hormone binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 1988; 54: 199–207
   PubMed Web of Science ®Google Scholar
• Carson M A, Tsai M J, Conneely O M. Structure-function properties of the chicken progesterone receptor A synthesized from complementary deoxyribonucleic acid. Mol Endocrinol 1987; 1: 179–801
   Google Scholar
• Hollenberg S M, Giguere V, Segui P. Colocalization of DNA-binding and transcriptional activation functions in the human glucocorticoid receptor. Cell 1987; 49: 39–46
   PubMed Web of Science ®Google Scholar
• Groyer A, Schweizer-Groyer G, Cadepond F. Antigluco-corticosteroid effects suggest why steroid hormone is required for receptors to bind DNA in vivo but not in vitro. Nature 1987; 328: 624–626
   PubMed Web of Science ®Google Scholar
• Linstedt A D, West N B, Brenner R M. Analysis of monomeric-dimeric states of the estrogen receptor with monoclonal anti-estrophilins. J Steroid Biochem 1986; 24: 677–686
   PubMedGoogle Scholar
• Martinez E, Givel F, Wahli W: The estrogen-responsive element as an inducible enhancer: DNA sequence requirements and conversion to a glucocorticoid-responsive element. EMBO J 1987; 6: 3719–3727
   PubMed Web of Science ®Google Scholar
• Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988; 55: 145–156
   PubMed Web of Science ®Google Scholar
• Lippman M E, Bolan G, Huff K K. The effects of estrogens anti-estrogens on hormone responsive breast cancer in long-term tissue culture. Cancer Res 1976; 36: 4595–4601
   PubMed Web of Science ®Google Scholar
• Allegra J C, Lippman M E. Growth a human breast cancer cell line in serum free medium and response to cytotoxic chemotherapy in patients with metastatic breast cancer. Cancer Res 1978; 83: 3823–3829
   Google Scholar
• Lippman M E, Bolan G, Huff K K. Interactions of antiestrogens with human breast cancer in long term tissue culture. Cancer Treat Rep 1972; 60: 1421–1430
   Google Scholar
• Aitken S C, Lippman M W. Hormonal regulation of de novo pyrimidine synthesis and utilization in human breast cancer cells in tissue culture. Cancer Res 1983; 43: 4681–4690
   PubMed Web of Science ®Google Scholar
• Aitken S C, Lippman M E. Effect of estrogens and antiestrogens on growth-regulatory enzymes in human breast cancer cells in tissue culture. Cancer Res 1985; 45: 1611–1620
   PubMed Web of Science ®Google Scholar
• Huff K K, Lippman M E. Hormonal control of plasminogen activator secretion in ZR-75–1 human breast cancer cells in culture. Endocrinology 1984; 114: 1665–1671
   PubMedGoogle Scholar
• Jakowlew S B, Breathnack R, Jeltsch J. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucl Acid Res 1984; 12: 2861–2874
   PubMed Web of Science ®Google Scholar
• Masiakowksi P, Breathnach R, Block J. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucl Acid Res 1982; 10: 7895–7903
   PubMed Web of Science ®Google Scholar
• Liotta L A, Rao C N, Weiner UM. Biochemical interactions of tumor cells with the basement membrane. Ann Rev Biochem 1986; 55: 1037–1040
   PubMed Web of Science ®Google Scholar
• Chalbos D, Rochefort H. Dual effects of the progestin R5O20 on proteins released by the T47D human breast cancer cells. J Biol Chem 1984; 259: 1231–1238
   PubMed Web of Science ®Google Scholar
• Rio M C, Belloco J P, Gairard U B. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci (USA) 1987; 84: 9243–9247
   PubMed Web of Science ®Google Scholar
• Brown A MC, Jeltsch J M, Roberts M. Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer line MCF-7. Proc Natl Acad Sci (USA) 1984; 81: 6344–6348
   PubMed Web of Science ®Google Scholar
• Schuurmans A LG, Bolt J, Voorhorst M M. Regulation of growth and epidermal growth factor receptor levels of prostate tumor cells by different steroids. Int J Cancer 1988; 42: 917–922
   PubMed Web of Science ®Google Scholar
• Schulz P, Bauer H W, Fittler F. Steroid hormone regulation of prostatic acid phosphatase expression in cultured human prostatic carcinoma cells. Biol Chem Hoppe Seyler 1985; 366: 1033–1039
   PubMed Web of Science ®Google Scholar
• Wilding G, Valverius E, Knabbe C. The role of transforming growth factor a in human prostate cancer cell growth. Prostate 1989; 14
   PubMedGoogle Scholar
• Schuurmans A, Bolt J, Mulder E. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell line LNCaP. Prostate 1988; 12: 55–63
   PubMed Web of Science ®Google Scholar
• Berns E M, DeBoer W, Mulder E. Androgen-dependent growth regulation of and release of specific proteins by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 1986; 9: 247–259
   PubMed Web of Science ®Google Scholar
• Kypeianou N, Isaacs J T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988; 122: 552–562
   PubMed Web of Science ®Google Scholar
• Montpetit M L, Lawless K R, Tenniswood M. Androgen-repressed messages in the rat ventral prostate. Prostate 1986; 8: 25–36
   PubMed Web of Science ®Google Scholar
• Buttyan R, Sawczak I, Benson M. Gene activity during regression of androgen dependent tissues. Am Assoc Cancer Res 1988; 29: 952
   Google Scholar
• Sporn M B, Todaro G J. Autocrine secretion and malignant transformation of cell. N Engl J Med 1980; 303: 878–890
   PubMed Web of Science ®Google Scholar
• Jakesz R, Smith C A, Aitken S: Influence of cell proliferation and all cycle phases on expression of estrogen receptor in MCF-7 breast cancer cells. Cancer Res 1984; 44: 619–625
   PubMed Web of Science ®Google Scholar
• Dickson R B, Lippman M E. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 1987; 8: 29–43
   PubMed Web of Science ®Google Scholar
• Carpenter G, Cohen S. Human epidermal growth factor and the proliferation of human fibroblasts. J Cell Physiol 1976; 88: 227–237
   PubMed Web of Science ®Google Scholar
• Stoscheck C M, King L E. Role of epidermal growth factor in carcinogenesis. Cancer Res 1986; 46: 1030–1037
   PubMed Web of Science ®Google Scholar
• Derynck R, Roberts A B, Winkler M E. Human transforming growth factor-a: precursor structure and expression in E. coli. Cell 1984; 38: 287–297
   PubMed Web of Science ®Google Scholar
• Todaro G J, Gryling C, DeLarco J E. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc Natl Acad Sci (USA) 1980; 77: 5258–5262
   PubMed Web of Science ®Google Scholar
• Downward J, Yarden Y, Mayes E. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307: 521–527
   PubMed Web of Science ®Google Scholar
• Bates S E, Davidson N E, Valverius E M. Expression of transforming growth factor-α and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol Endocrinol 1988; 2: 543–555
   PubMed Web of Science ®Google Scholar
• Clark A JL, Ishii S, Richert N. Epidermal growth factor regulates the expression of its own receptor. Proc Natl Acad Sci (USA) 1985; 82: 8374–8378
   PubMed Web of Science ®Google Scholar
• Clarke R, Lippman M E, Glanz P. MCF-7 breast carcinoma cells expressing transfected TGF alpha sequences continue to require estrogen for growth and tumorigenicity. J Cell Biochem 1988; 12A: C128
   Google Scholar
• Fitzpatrick S L, Brightwell J, Wittlieff J L. Epidermal growth factor binding by breast tumor biopsies and relationship to estrogen receptor and progestin receptor levels. Cancer Res 1984; 44: 3448–3453
   PubMed Web of Science ®Google Scholar
• Sainsbury J RC, Sherbet G V, Farndon J R. Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet 1985; 1: 364–366
   PubMed Web of Science ®Google Scholar
• Davidson N E, Gelmann E P, Lippman M R. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1987; 1: 216–223
   PubMedGoogle Scholar
• Filmus J, Pollack M N, Cailleau R: MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 1985; 128: 898–905
   PubMed Web of Science ®Google Scholar
• Zajchowski D, Band V, Pauzie N. Expression of growth factors and oncogenes in normal and tumor-derived human mammary epithelial cells. Cancer Res 1988; 48: 7041–7047
   PubMed Web of Science ®Google Scholar
• Fernandez-Pol J A, Klos D J, Grant G A. Purification and biological properties of type β transforming growth factor from mouse transformed cells. Cancer Res 1986; 46: 5153–5161
   PubMed Web of Science ®Google Scholar
• Huff K K, Kaufman D, Gabbay K H: Human breast cancer cells secrete an insulin-like growth factor-I-related polypeptide. Cancer Res 1986; 46: 4613–4619
   PubMed Web of Science ®Google Scholar
• Furlanetto R W, DiCarlo N. Somatomedin-C receptors and growth effects in human breast cells maintained in long-term tissue culture. Cancer Res 1984; 44: 2122–2128
   PubMed Web of Science ®Google Scholar
• Huff K K, Knabe C, Kaufman D. Hormonal regulation of insulin-like growth factor I (IGF-I) secretion from MCF-7 human breast cancer cells. J Cell Biochem Suppl 1987; 11A: 28
   Google Scholar
• Pekonen F, Partanen S, Makinen T. Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 1988; 48: 1343–1347
   PubMed Web of Science ®Google Scholar
• Yee D, Cullen K J, Paik S. Insulin-like growth factor II mRNA expression in human breast cancer. Cancer Res 1988; 48: 6691–6696
   PubMed Web of Science ®Google Scholar
• Matuo Y, Nishi N, Tanaka H. Production of IGFII-related peptide by an anaplastic cell line (AT-3) established from the Dunning prostatic carcinoma of rats. In Vitro Cell Dev Biol 1988; 24: 1053–1056
   PubMed Web of Science ®Google Scholar
• Bronzert D A, Pantazis P, Antoniades H N. Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci (USA) 1987; 84: 5763–5767
   PubMed Web of Science ®Google Scholar
• Yarden Y, Escobedo J A, Kwang W J. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factors. Nature 1986; 323: 226–228
   PubMed Web of Science ®Google Scholar
• Sitaras N M, Sariban E, Bravo M. Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res 1930–1935; 48, 1988
   Google Scholar
• Tucker R F, Branum E L, Shipley G D. Specific binding to cultured cells of 1251-labeled transforming growth factor β from human platelets. Proc Natl Acad Sci (USA) 1984; 81: 6157–6161
   Google Scholar
• Sporn M B, Roberts A B, Wakefield L M. Transforming growth factor-β: biological function and chemical structure. Science 1986; 233: 532–534
   PubMed Web of Science ®Google Scholar
• Massague J. Epidermal growth factor-like transforming growth factor. J Biol Chem 1983; 258: 13606–13613
   PubMed Web of Science ®Google Scholar
• Roberts A B, Anzano M A, Wakefield L M: type 0 transforming growth factor: a Afunctional regulator of cellular growth. Proc Natl Acad Sci (USA) 1985; 82: 119–123
   PubMed Web of Science ®Google Scholar
• Knabbe C, Lippman M E, Wakefield L M. Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells. Cell 1987; 48: 417–428
   PubMed Web of Science ®Google Scholar
• Arteaga C L, Tandon A K, VonHoff D D. Transforming growth factor-β: potential autocrine growth inhibition of estrogen receptor-negative human breast cancer cells. Cancer Res 1988; 48: 3898–3904
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Ennis B W, Deschauer B. Transforming growth factors type β1 and β2 but not Muellerian inhibiting substance are equipotent growth inhibitors of human breast cancer cell lines. J Cell Physiol 1989; 141: 353–361
   PubMed Web of Science ®Google Scholar
• Bronzert D A, Greene G L, Lippman M E. Selection and characterization of breast cancer cell line resistant to the anti-estrogen LY 117018. Endocrinology 1985; 117: 1409–1417
   PubMed Web of Science ®Google Scholar
• Ervin P R, Kaminski M S, Cody R L. Production of mammastatin, a tissue-specific growth inhibitor, by normal human mammary cells. Science 1989; 244: 1585–1587
   PubMed Web of Science ®Google Scholar
• Wilding G, Zugmeier G, Knabbe C. Differential effects of transforming growth factor-β on human prostate cancer cells in vitro. Molec Cell Endocrinol 1989; 62: 78–87
   Google Scholar
• Gospodardwicz D, Neufeld G, Schweigerer L. Fibroblast growth factor. Molec Cell Endocrinol 1986; 46: 187–204
   PubMed Web of Science ®Google Scholar
• Zhan X, Bates B, Hux. The human FGF5 oncogene encodes a novel protein related to fibroblast growth factors. Molec Cell Biol 1988; 8: 3487–3495
   PubMed Web of Science ®Google Scholar
• Story M T, Sasse J, Jacobs S C. Prostatic growth factor: purification and structural relationship to basic fibroblast growth factor. Biochemistry 1987; 26: 3843–3849
   PubMed Web of Science ®Google Scholar
• Crabb J W, Armes L G, Carr S A. The complete primary structure of prostatropin, a prostate epithelial cell growth factor. Biochemistry 1986; 25: 4928–4933
   Google Scholar
• Mansson P E, Adams P, Kan M. Hermann-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res 1989; 49: 2485–2494
   PubMed Web of Science ®Google Scholar
• Matuo Y, Nishi N, Matsui S: Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor. Cancer Res 1987; 47: 188–192
   PubMed Web of Science ®Google Scholar
• Sherwood E, Wood C, Jacoby J. Stromal-epithelial interactions in the human prostate: basic fibroblast growth factor as a mediator of benign prostatic growth. Am Assoc Cancer Res 1989; 30: 280
   Google Scholar
• Maohama S, Li D, Nanri H. Purification and partial characterization of prostate-derived growth factor. Proc Natl Acad Sci (USA) 1986; 83: 8162–8166
   PubMed Web of Science ®Google Scholar
• Flamm S L, Wellstein A, Lupu R. Expression of fibroblast growth factor peptides in normal and malignant human mammary epithelial cells. Am Assoc Cancer Res 1989; 30: 278
   Google Scholar
• McGuire W L, Carbone P P, Sears M E. Estrogen receptors in human breast cancer: An overview. Estrogen Receptors in Human Breast Cancer, WL McGuire, PP Carbone, ME Sears. Raven Press, New York 1975
   Google Scholar
• McGuire W L. The usefulness of steroid hormone receptors in the management of primary and advanced breast cancer. Breast Cancer: Experimental and Clinical Aspects, HT Mourid-son, T Palshof. Pergamon Press, New York 1980
   Google Scholar
• Kasid A, Lippman M E, Papageorge A G. Transfection of v-ras-H DNA into MCF-7 human breast cancer cells bypasses dependence on estrogen for tumorigenicity. Science 1985; 228: 725–728
   PubMed Web of Science ®Google Scholar
• Dickson R B, Kasid A, Huff K K. Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17β-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci (USA) 1987; 84: 837–841
   PubMed Web of Science ®Google Scholar
• Sommers C L, Papageorge A, Wilding G. The role of the rasH oncogene in tumorigenesis of MCF-7 human breast cancer cells. Cancer Res 1990; 50: 67–71
   PubMed Web of Science ®Google Scholar
• Cormier E M, Wolf M F, Jordan V C. Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implications for paracrine-regulated breast cancer growth. Cancer Res 1989; 49: 576–580
   PubMed Web of Science ®Google Scholar
• Robinson S P, Jordan V C. The paracrine stimulation of MCF-7 cells by MDA-MB-231 cells: Possible role in antiestrogen failure. Eur J Cancer Clin Oncol 1989; 25: 493–497
   PubMedGoogle Scholar
• Chang C, Kokontis J, Liao S. Structural analysis of complementary DNA and amino acid sequences of human and rat androgen receptors. Proc Natl Acad Sci (USA) 1988; 85: 7211–7215
   PubMed Web of Science ®Google Scholar
• Brown T R, Lubahn D B, Wilson E M. Deletion of the steroid-binding domain of the human androgen receptor gene in one family with complete androgen insensitivity syndrome: Evidence for further genetic heterogeneity in this syndrome. Proc Natl Acad Sci (USA) 1988; 85: 8151–8155
   PubMed Web of Science ®Google Scholar
• Wilding G W, Chen M, Gelmann E. Aberrant response in vitro of hormone responsive prostate cancer cells to antiandrogens. Prostate 1989; 14: 103–115
   PubMed Web of Science ®Google Scholar
• Dabre P D, King R JB. Progression to steroid insensitivity can occur irrespective of the presence of functional steroid receptors. Cell 1987; 51: 521–528
   PubMed Web of Science ®Google Scholar
• Osborne C K, Boldt D H, Clark G M. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early Gl phase. Cancer Res 1983; 43: 3583–3585
   PubMed Web of Science ®Google Scholar
• Sutherland R L, Hall R E, Taylor I W. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and pleateau-phase cells. Cancer Res 1983; 43: 3993–4006
   Google Scholar
• Osborne C K, Boldt D H, Estrada P. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture. Cancer Res 1984; 44: 1433–1439
   PubMed Web of Science ®Google Scholar
• Jordan V C. Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Rev Endocr Rel Cancer October, 1978; 49–55
   Google Scholar
• Jordan V C, Mirecki D M, Gottardis M M. Continuous tamoxifen treatment prevents the appearance of mammary tumors in a model of adjuvant therapy. Adjuvant Therapy of Cancer, SE Jones, SE Salmon. Grune and Stratton, New York 1984
   Google Scholar
• Gottardis M M, Robinson S P, Jordan V C. Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 1988; 30: 311–314
   PubMedGoogle Scholar
• Osborne K C, Hobbs K, Clark G M. Effect of estrogens and anti-estrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 1985; 45: 584–590
   PubMed Web of Science ®Google Scholar
• Jordan V C. Biochemical pharmacology of antiestrogen action. Pharm Rev 1984; 36: 245–276
   PubMed Web of Science ®Google Scholar
• Sutherland R L, Mester J, Baulieu E E. Tamoxifen is a potent “pure” antiestrogen in the chick oviduct. Nature (Lond) 1977; 267: 434–435
   PubMed Web of Science ®Google Scholar
• Lyman S D, Jordan V C. Metabolism of tamoxifen and its uterotrophic activity. Biochem Pharm 1985; 34: 2787–2794
   PubMed Web of Science ®Google Scholar
• Gottardis M M, Robinson S P, Satyaswaroop P G. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 1988; 48: 812–815
   PubMed Web of Science ®Google Scholar
• Jordan V C. Long-term tamoxifen therapy for breast cancer. Recent Advances in Oncology, VT Devita, S Hellman, SA Rosenberg. Lippincott, Philadelphia 1989
   Google Scholar
• Ribeiro G, Swindell R. The Christie Hospital adjuvant tamoxifen trial-status at 10 years. Br J Cancer 1988; 57: 601–603
   PubMed Web of Science ®Google Scholar
• Ludwig Breast Cancer Group. Randomized trial of chemo-endocrine therapy, endocrine therapy and mastectomy alone in postmenopausal patients with operable breast cancer and axillary node metastases. Lancet 1984; 1: 1256–1260
   PubMed Web of Science ®Google Scholar
• Nolvadex Trial Adjuvant Organization. Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988; 57: 608–611
   PubMed Web of Science ®Google Scholar
• Breast Cancer Committee Trials, Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer. The Scottish trial. Lancet 1987; 2: 171–175
   PubMed Web of Science ®Google Scholar
• Delozier T, Julien J-P, Juret P. Adjuvant tamoxifen in postmenopausal breast cancer: Preliminary results of a randomized trial. Breast Cancer Res Treat 1986; 7: 105–110
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino J, Redmond C. A randomized trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479–484
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Engl J Med 1988; 319: 1681–1692
   PubMed Web of Science ®Google Scholar
• Grem J L, Cabone P P. Review: Adjuvant hormonotherapy for breast cancer. Eur J Cancer Clin Oncol 1986; 22: 235–239
   PubMedGoogle Scholar
• Neri R O, Florance K, Koziol P. A biological profile of a nonsteroidal antiandrogen SCH-13521 (4′-nitro-3′-trifluoro-methylisobutyranilde). Endocrinology 1972; 91: 427–437
   PubMed Web of Science ®Google Scholar
• Stolier B, Albert D J. SCH 13521 in the treatment of advanced carcinoma of the prostate. J Urol 1974; 111: 803–807
   PubMed Web of Science ®Google Scholar
• Prout GR, Jr., Irwin RJ, Jr., Klimer B. Prostatic cancer and SCH 13521: II. Histological alterations and the pituitary gonadal axis. J Urol 1975; 113: 834–840
   PubMed Web of Science ®Google Scholar
• Jacobo E, Schmidt J D, Weinstein S H. Comparison of fiutamide (SCH 13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology 1976; 8: 231–233
   PubMedGoogle Scholar
• Sogani P C, Vagaiwala M R, Whitemore W, Jr. Experience with fiutamide in patients with advanced prostatic cancer without prior endocrine therapy. Cancer 1984; 54: 744–750
   PubMed Web of Science ®Google Scholar
• Narayana A S, Loening S A, Culp D A. Fiutamide in the treatment of metastatic carcinoma of the prostate. Br J Urol 1981; 53: 152–153
   PubMedGoogle Scholar
• Labrie F, Dupont A, Belanger A. Treatment of prostate cancer with gonadotropin releasing hormone agonists. Endocr Rev 1986; 7: 67–74
   PubMed Web of Science ®Google Scholar
• Beland G, Elhilail M, Gradet Y. Total androgen blockade vs oricbiectomy in stage D2 prostate cancer. Prostate Cancer Part A: Research, Endocrine Treatment and Histopathology, S Khoury, R Kuss, G Murphy. Alan R. Iiss, New York 1987; 391–400
   Google Scholar
• Brisset J M, Boccon-Gibod B, Hetal Botto. Anandron(RU23908) associated to surgical castration in previously untreated stage D prostate cancer: A multicenter comparative study of two doses of the drug and a placebo. Prostate Cancer Part A: Research, Endocrine Treatment and Histopathology, S Khoury, R Kuss, G Murphy. Alan R. Liss, New York 1987; 411–422
   Google Scholar
• Iverson P, Wolf H, Hvidt V. Zoladex plus fiutamide vs orichiectomy in the treatment of advanced prostatic cancer. Am Soc Clin Oncol Proc 1989; 348A: 713
   Google Scholar
• Trachtenberg J, Beland G, Mostafa M. A randomized trial of total androgen ablation vs oriectomy in patients with metastatic prostatic cancer. Am Soc Clin Oncol Proc 1989; 347A: 712
   Google Scholar
• Crawford E D, Eisenberger M A, McLeod D. A controlled trial of leuprolide with and without fiutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–424
   PubMed Web of Science ®Google Scholar
• Levine A, Cohen Gill P. Suramin antiviral therapy in the acquired immunodeficiency syndrome. Ann Int Med 1986; 105: 32–37
   PubMed Web of Science ®Google Scholar
• Spigelman Z, Dow A, Kennedy S. Antiproliferative effects of suramin on lymphoid cells. Cancer Res 1987; 47: 4696–4698
   Google Scholar
• Garrett J, Coughlin S, Nima H. Blockade of autocrine stimulation in simian sarcoma virus transformed cells reverses down-regulation of platelet-derived growth factor receptors. Proc Natl Acad Sci (USA) 1984; 81: 7466–7470
   PubMed Web of Science ®Google Scholar
• Betsholtz C, Johnsson A, Heldin C. Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor induced mitogenesis by suramin. Proc Natl Acad Sci (USA) 1986; 83: 6440–6444
   PubMed Web of Science ®Google Scholar
• Coffey R, Leof E, Shipley G. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J Cell Physiol 1987; 132: 143–148
   PubMed Web of Science ®Google Scholar
• Winnann M, LaRocca R V, Stein C A. Effect of suramin on proliferation of human prostate carcinoma. Am Assoc Cancer Res 1989; 30: 1234
   Google Scholar
• Knabbe C, Kellner U, Schmahl M. Suramin inhibits growth of human prostate carcinoma cells by inactivation of growth factor action. Am Assoc Cancer Res 1989; 30: 1172
   Google Scholar
• Bergh J. Suramin is a potent inhibitor of the cell proliferation in human non-small cell lung cancer cell lines. Am Soc Clin Oncol 1989; 8: 24
   Google Scholar
• Wade T P, Kasid A, Stein C. Suramin interferes with TGF-beta induced inhibition of human renal cell carcinoma. Am Assoc Cancer Res 1989; 30: 276
   Google Scholar
• Wellstein A, Zugmaier G, Califano I. Xylan polyhydrogen sulfate inhibits fibroblast growth factor dependent growth of human tumor cells. Am Assoc Cancer Res 1989; 30: 2320
   Google Scholar
• Stein C A, LaRocca R V, Thomas R. An anticancer drug with a unique mechanism of action. J Gin Oncol 1989; 7: 499–508
   Web of Science ®Google Scholar
• Myers C E, Stein C, LaRocca R. Suramin: an antagonist of heparin-binding tumor growth factors with activity against a broad spectrum of human tumors. Am Soc Clin Oncol 1989; 8: 256
   Google Scholar
• LaRocca R, Stein C, Myers C. Suramin induced acute polyneuropathy. Am Soc Clin Oncol 1989; 8: 277
   Google Scholar
• Cooper M, LaRocca R, Stein C. Pharmacokinetic monitoring is necessary for the safe use of suramin as an anticancer drug. Am Assoc Cancer Res 1989; 30: 963
   Google Scholar
• Arceci R J, Croop J M, Horwitz S B. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci (USA) 1988; 85: 4350–4354
   PubMed Web of Science ®Google Scholar
• Yang C P, DePinho S G, Greenberger L M. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. J Biol Chem 1989; 264: 782–788
   PubMed Web of Science ®Google Scholar
• Kyprianou N, English H F, Isaacs J T. Activation of programmed cell death in androgen-dependent and androgen independent prostatic tumors. Am Assoc Cancer Res 1989; 30: 1181
   Google Scholar